Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 4881

Next Previous
X
Search
Drug Profile

REC 4881

Alternative Names: REC-4881; TAK-733

Latest Information Update: 23 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exscientia; Takeda
  • Developer Recursion Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Familial adenomatous polyposis; Solid tumours
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 08 Aug 2024 Recursion Pharmaceuticals and Exscientia agree to co-promote and co-develop REC 4881 for familial adenomatous polyposis
  • 15 Jan 2024 Phase-II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06005974)
  • 08 Aug 2023 Recursion Pharmaceuticals plans a phase II trial in Solid tumours (Inoperable/Unresectable, Late stage disease, Metastatic disease) in Q4 of 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top